PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
出版年份 2021 全文链接
标题
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
作者
关键词
-
出版物
Frontiers in Cardiovascular Medicine
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-03-23
DOI
10.3389/fcvm.2021.639727
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation
- (2021) Beili Xu et al. Frontiers in Oncology
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- (2020) Nicholas A. Marston et al. CIRCULATION
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
- (2020) Vittoria Cammisotto et al. Antioxidants
- PCSK9 and LRP5 in macrophage lipid internalization and inflammation
- (2020) Lina Badimon et al. CARDIOVASCULAR RESEARCH
- An Update on the Role of PCSK9 in Atherosclerosis
- (2020) Ece Yurtseven et al. Journal of Atherosclerosis and Thrombosis
- Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway
- (2020) Xin Li et al. BIOMEDICINE & PHARMACOTHERAPY
- PCSK9 inhibition and inflammation: A narrative review
- (2019) Massimiliano Ruscica et al. ATHEROSCLEROSIS
- Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
- (2019) Susanne Schuster et al. Scientific Reports
- Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome
- (2019) Hideki Yano et al. Journal of Cardiology
- Platelet function and activation markers in primary hypercholesterolemia treated with PCSK9 monoclonal antibody: a 12-month follow-up
- (2019) Cristina Barale et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines
- (2019) Shijie Liu et al. CARDIOVASCULAR RESEARCH
- Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
- (2019) Ye-Xuan Cao et al. Journal of Translational Medicine
- PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque
- (2018) A. Liu et al. JOURNAL OF INTERNAL MEDICINE
- PCSK9 as a Positive Modulator of Platelet Activation
- (2018) Marina Camera et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases
- (2018) Anja Hofmann et al. VASCULAR PHARMACOLOGY
- Naringin Activates AMPK Resulting in Altered Expression of SREBPs, PCSK9, and LDLR To Reduce Body Weight in Obese C57BL/6J Mice
- (2018) Guo-Guang Sui et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Effect of statins on measures of coagulation: potential role of low-density lipoprotein receptors
- (2018) Francesco Paciullo et al. EUROPEAN HEART JOURNAL
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
- (2017) Sophie J. Bernelot Moens et al. EUROPEAN HEART JOURNAL
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
- (2017) Eliano P. Navarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- PCSK9 and Atherosclerosis - Lipids and Beyond
- (2017) Michael D. Shapiro et al. Journal of Atherosclerosis and Thrombosis
- Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
- (2017) Daniele Pastori et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
- (2017) Jiao Li et al. Molecular Medicine Reports
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-analysis of the Literature
- (2017) Vera Gessi et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
- (2017) Hui Wang et al. Scientific Reports
- Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis
- (2016) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
- (2016) Bertrand Cariou et al. ATHEROSCLEROSIS
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE
- (2016) Karin Leander et al. CIRCULATION
- Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
- (2016) Wuxiang Xie et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Oxidized Low‐Density Lipoprotein (OxLDL)–Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let‐7c Is Integral to the Effect
- (2016) Johan Frostegård et al. Journal of the American Heart Association
- LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
- (2016) Eguzkine Ochoa et al. PLoS One
- Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
- (2015) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary PreventionSignificance
- (2015) Yiming M. Zhu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation
- (2015) M.-Y. Shen et al. BLOOD
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
- (2015) Paul M. Ridker et al. EUROPEAN HEART JOURNAL
- The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
- (2015) Sha Li et al. Journal of Atherosclerosis and Thrombosis
- K Domain CR9 of Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) Is Critical for Aggregated LDL-induced Foam Cell Formation from Human Vascular Smooth Muscle Cells
- (2015) Paula Costales et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism
- (2014) Roberto Carnevale et al. ATHEROSCLEROSIS
- Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis
- (2014) Meaghan D. Waltmann et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Mechanisms of Plaque Formation and Rupture
- (2014) Jacob Fog Bentzon et al. CIRCULATION RESEARCH
- Pathophysiology of Acute Coronary Syndrome
- (2014) Carlos G. Santos-Gallego et al. Current Atherosclerosis Reports
- Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
- (2014) Susan Kühnast et al. JOURNAL OF LIPID RESEARCH
- Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages
- (2014) Ekhtear Hossain et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Resistance and intolerance to statins
- (2014) Ž. Reiner NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
- (2014) Gergana Galabova et al. PLoS One
- New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
- (2013) Amirhossein Sahebkar et al. CARDIOVASCULAR DRUGS AND THERAPY
- Lipopolysaccharide Activates Toll-like Receptor 4 (TLR4)-mediated NF-κB Signaling Pathway and Proinflammatory Response in Human Pericytes
- (2013) Irene Guijarro-Muñoz et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
- (2013) Gaétan Mayer et al. Drug Design Development and Therapy
- Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in ldlr−/−mice fed on a high-fat diet
- (2012) Gergana M. Deevska et al. BIOSCIENCE REPORTS
- Loss- and Gain-of-function PCSK9 Variants
- (2012) Suzanne Benjannet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
- (2012) Marie-Luise von Brühl et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages
- (2011) Daniel Baitsch et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice
- (2011) K. R. Machlus et al. BLOOD
- Unexpected roles for PCSK9 in lipid metabolism
- (2011) Anne K Soutar CURRENT OPINION IN LIPIDOLOGY
- Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages
- (2011) Maria Borrell-Pagès et al. EUROPEAN HEART JOURNAL
- PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway
- (2011) Chun-Yan Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Mechanisms of LDL oxidation
- (2010) Hiroshi Yoshida et al. CLINICA CHIMICA ACTA
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- Extracellular DNA traps promote thrombosis
- (2010) T. A. Fuchs et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Endothelium, venous thromboembolism and ischaemic cardiovascular events
- (2009) P. Gresele et al. THROMBOSIS AND HAEMOSTASIS
- Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells
- (2008) Tommaso Fasano et al. ATHEROSCLEROSIS
- A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein
- (2008) Kan Chen et al. CIRCULATION RESEARCH
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search